摘要
目的:探讨替米沙坦和雷米普利单用或联合用药治疗原发性轻、中度高血压的疗效和安全性。方法:158例轻、中度原发性高血压患者随机分为替米沙坦80 mg·d^(-1)组、雷米普利5 mg·d^(-1)组和替米沙坦80 mg·d^(-1)+雷米普利2.5 mg·d^(-1)组,治疗8周后比较三组患者降压的总有效率,观察不良反应。结果:治疗后各组血压明显降低(P<0.05),单用组间差异无统计学意义(P>0.05),而联合用药组较单独用药组更明显(P<0.01)。替米沙坦和联合用药组的不良反应少见。结论:替米沙坦和雷米普利联合用药可以有效控制轻、中度原发性高血压,安全性好。
Objective ： To investigate the effect and safety of telmisartan and ramipril alone or combination in the treatment of patients with mild to moderate hypertension. Method： 158 patients with mild to moderate hypertension were randomly divided into three groups ： Group A ： telmisartan （ 80 mg ·d^-1 ） , Group B ： ramipril （ 5 mg ·d^-1 ） and Group C ： telmisartan （80 mg·d^-1 ） ＋ ramipril （2.5 mg ·d^-1 ） . After 8 weeks, their total effective rates of lowering blood pressure were compared, and their adverse reactions were observed. Result：After therapy, all the groups showed their significant decreases of blood pressure. There was no statistical difference between Groups A and B , but significant differences were observed between Group C and Group A or B. Fewer adverse effects were observed in Group A and C. Conclusion：Combined with telmisartan and ramipril could effectively lower blood pressure in mild to moderate hypertersion patients and had fewer adverse reactions.
出处
《药物流行病学杂志》
CAS
2010年第11期611-613,共3页
Chinese Journal of Pharmacoepidemiology
